| TCGA Cohort (N = 356) | FUSCC Cohort (N = 276) |  | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cases | PD-1 | P a | PD-L1 | P a | Cases | PD-1 | P a | PD-L1 | P a | |||||
No. (%) | Low | High | Â | Low | High | Â | No. (%) | Low | High | Â | Low | High | Â | |
Age (years) | ||||||||||||||
  ≤ 60 | 137 (38.5) | 68 (41.2) | 69 (36.1) | 0.325 | 21 (38.2) | 116 (38.5) | 0.960 | 170 (61.6) | 100 (58.8) | 70 (66.0) | 0.231 | 85 (61.6) | 85 (61.6) | 1.000 |
  > 60 | 219 (35.7) | 97 (58.8) | 122 (63.9) |  | 34 (61.8) | 185 (61.5) |  | 106 (8.4) | 70 (41.7) | 36 (34.0) |  | 53 (38.4) | 53 (38.4) | |
Gender | ||||||||||||||
 Male | 199 (55.9) | 91 (55.2) | 108 (56.5) | 0.792 | 33 (60.0) | 166 (55.1) | 0.505 | 166 (60.1) | 102 (60.0) | 64 (60.4) | 0.950 | 88 (63.8) | 78 (56.5) | 0.219 |
 Female | 157 (44.1) | 74 (44.8) | 83 (43.5) |  | 22 (40.0) | 135 (44.9) |  | 110 (39.9) | 68 (40.0) | 42 (39.6) |  | 50 (36.2) | 60 (43.5) | |
Primary site | ||||||||||||||
 Colon | 269 (75.6) | 115 (69.7) | 154 (80.6) | 0.017 | 46 (83.6) | 223 (74.1) | 0.130 | 129 (46.7) | 84 (49.4) | 45 (42.5) | 0.260 | 65 (47.1) | 64 (46.4) | 0.904 |
 Rectum | 87 (24.4) | 50 (30.3) | 37 (19.4) |  | 9 (16.4) | 78 (25.9) |  | 147 (53.3) | 86 (50.6) | 61 (57.5) |  | 73 (52.9) | 74 (53.6) | |
Histological type | ||||||||||||||
 Adenocarcinoma | 316 (88.8) | 149 (90.3) | 167 (87.4) | 0.393 | 50 (90.9) | 266 (88.4) | 0.584 | 261 (94.6) | 158 (92.9) | 103 (97.2) | 0.132 | 132 (95.6) | 129 (93.5) | 0.426 |
 Mucinous/SRCC | 40 (11.2) | 16 (9.7) | 24 (12.6) |  | 5 (9.1) | 35 (11.6) |  | 15 (5.4) | 12 (7.1) | 3 (2.8) |  | 6 (4.3) | 9 (6.5) | |
T stage | ||||||||||||||
 Tis-T2 | 68 (19.1) | 29 (17.6) | 39 (20.4) | 0.386 | 9 (16.4) | 78 (25.9) | 0.844 | 43 (15.6) | 24 (14.1) | 19 (17.9) | 0.588 | 19 (13.8) | 24 (17.4) | 0.044 |
 T3 | 242 (68.0) | 118 (71.5) | 124 (64.9) |  | 39 (70.9) | 203 (67.4) |  | 32 (19.6) | 32 (18.8) | 22 (20.8) |  | 20 (14.5) | 34 (24.6) | |
 T4 | 46 (12.9) | 18 (10.9) | 28 (14.7) |  | 7 (12.7) | 39 (13.0) |  | 179 (64.8) | 114 (67.1) | 65 (61.3) |  | 99 (71.7) | 80 (58.0) | |
N stage | ||||||||||||||
 N0 | 194 (54.5) | 83 (50.3) | 111 (58.1) | 0.185 | 23 (41.8) | 171 (56.8) | 0.101 | 120 (43.5) | 70 (41.2) | 50 (47.2) | 0.432 | 57 (41.3) | 63 (45.7) | 0.767 |
 N1 | 98 (27.5) | 53 (32.1) | 45 (23.6) |  | 18 (32.7) | 80 (26.6) |  | 83 (30.1) | 49 (28.8) | 33 (31.1) |  | 43 (31.2) | 40 (29.0) | |
 N2 | 64 (18.0) | 29 (17.6) | 35 (18.3) |  | 14 (25.5) | 50 (16.6) |  | 73 (26.4) | 50 (29.4) | 23 (21.7) |  | 38 (27.5) | 35 (25.4) | |
M stage | ||||||||||||||
 M0 | 245 (68.8) | 109 (66.1) | 136 (71.2) | 0.107 | 34 (61.8) | 211 (70.1) | 0.284 | 234(84.8) | 137 (80.6) | 97 (91.5) | 0.01 | 108(78.3) | 126 (91.3) | 0.003 |
 M1 | 48 (13.5) | 29 (17.6) | 19 (9.9) |  | 11 (20.0) | 37 (12.3) |  | 42(15.2) | 33 (19.4) | 9 (8.5) |  | 30(21.7) | 12 (8.7) | |
 Mx | 63 (17.7) | 27 (16.4) | 36 (18.8) |  | 10 (18.2) | 53 (17.6) |  |  |  |  |  |  |  | |
Pathological grading | ||||||||||||||
 Well/moderate | NA | 204(73.9) | 67 (73.6) | 137 (74.1) | 0.498 | 102(73.9) | 102 (73.9) | 1.000 | ||||||
 Poor/anaplastic | 56(20.3) | 18 (19.8) | 38 (20.5) |  | 28(20.3) | 28 (20.3) | ||||||||
 Unknown | 16(5.8) | 6 (6.6) | 10 (5.4) |  | 8(5.8) | 8 (5.8) | ||||||||
Venous invasion | ||||||||||||||
 Negative | 235 (66.0) | 105 (63.6) | 130 (68.1) | 0.557 | 28 (50.9) | 207 (68.8) | 0.026 | 184(66.7) | 107 (62.9) | 77 (72.6) | 0.104 | 85(61.6) | 99 (71.7) | 0.193 |
 Positive | 70 (19.7) | 33 (20.0) | 37 (19.4) |  | 14 (25.5) | 56 (18.6) |  | 88(31.9) | 59 (34.7) | 29 (27.4) |  | 51(37.0) | 37 (26.8) | |
 Unknown | 51 (14.3) | 27 (16.4) | 24 (12.6) |  | 13 (23.6) | 38 (12.6) |  | 4(1.4) | 4 (2.4) | 0 (0.0) |  | 2(1.4) | 2 (1.4) | |
Nervous invasion | ||||||||||||||
 Negative | NA | 231 (83.7) | 75 (82.4) | 156 (84.3) | 0.181 | 118 (85.5) | 231 (83.7) | 0.337 | ||||||
 Positive | 45 (16.3) | 16 (17.6) | 29 (15.7) |  | 20 (14.5) | 45 (16.3) | ||||||||
TILs extent | ||||||||||||||
 Low | 47 (13.2) | 33 (20.0) | 14 (7.3) | 0.002 | 16 (29.1) | 31 (10.3) | <0.001 | 129 (46.7) | 85 (50.0) | 44 (41.5) | 0.169 | 59 (42.8) | 70 (50.7) | 0.184 |
 High | 93 (26.1) | 42 (25.5) | 51 (26.3) |  | 17 (30.9) | 76 (25.2) |  | 147 (53.3) | 85 (50.0) | 62 (58.5) |  | 79 (57.2) | 68 (49.3) | |
 Unknown | 216 (60.7) | 90 (54.5) | 126 (66.0) |  | 22 (40.0) | 194 (64.5) |  |  |  |  |  |  |  | |
No. of LNs dissected | ||||||||||||||
  < 12 | 80 (22.5) | 42 (25.5) | 38 (19.9) | 0.219 | 14 (25.5) | 56 (18.6) | 0.658 | 39 (14.1) | 24 (14.1) | 15 (14.2) | 0.994 | 16 (11.6) | 23 (16.7) | 0.226 |
  ≥ 12 | 247 (69.4) | 107(64.8) | 140 (73.3) |  | 38 (69.1) | 209 (69.4) |  | 237 (85.9) | 146 (85.9) | 91 (85.8) |  | 122 (88.4) | 115 (83.3) | |
 Unknown | 29 (8.1) | 16 (9.7) | 13 (6.8) |  | 3 (5.5) | 26 (8.6) |  |  |  |  |  |  |  | |
MS status/MMR status | ||||||||||||||
 MSS/MMR-proficient | 243 (68.3) | 123 (74.5) | 120 (62.8) | 0.018 | 39 (70.9) | 204 (67.8) | 0.646 | 176 (63.8) | 102 (60.0) | 74 (69.8) | 0.099 | 93 (67.4) | 83 (60.1) | 0.21 |
 MSI/MMR-deficient | 113 (31.7) | 42 (25.5) | 71 (37.2) |  | 16 (29.1) | 97 (32.2) |  | 100 (36.2) | 68 (40.0) | 32 (30.2) |  | 45 (32.6) | 55 (39.9) | |
CEA (μl/ml) | ||||||||||||||
  ≤ 5 | 144 (40.4) | 59 (35.8) | 85 (44.5) | 0.151 | 13 (23.6) | 131 (43.5) | 0.007 | 170 (61.6) | 106 (62.4) | 64 (60.4) | 0.532 | 80 (58.0) | 90 (65.2) | 0.382 |
  > 5 | 85 (23.9) | 39 (23.6) | 46 (24.1) |  | 13 (23.6) | 72 (23.9) |  | 95 (34.4) | 59 (34.7) | 36 (34.0) |  | 51 (37.0) | 44 (31.9) | |
 Unknown | 127 (35.7) | 67 (40.6) | 60 (31.4) |  | 29 (52.7) | 98 (32.6) |  | 11 (4.0) | 5 (2.9) | 6 (5.7) |  | 7 (5.1) | 4 (2.9) | |
Adjuvant chemotherapy | ||||||||||||||
 Yes | NA | 189 (68.5) | 58 (63.7) | 131 (70.8) | 0.082 | 89 (64.5) | 100 (72.5) | 0.05 | ||||||
 No | 49 (17.8) | 15 (16.5) | 34 (18.4) |  | 23 (16.7) | 26 (18.8) | ||||||||
 Unknown | 38 (13.7) | 18 (19.8) | 20 (10.8) |  | 26 (18.8) | 12 (8.7) |